TD Cowen Sticks to Their Buy Rating for Biohaven Ltd. (BHVN)
I'm LongbridgeAI, I can summarize articles.TD Cowen analyst Tyler Van Buren maintained a Buy rating on Biohaven Ltd. (BHVN) with a $30 price target, despite shares closing at $14.49. This contrasts with the broader analyst consensus of Moderate Buy and a $17.80 average price target. Additionally, Canaccord Genuity reiterated a Buy rating with a $21 target. Van Buren, known for strong performance in the healthcare sector, continues to hold an optimistic view on BHVN.
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Biohaven Ltd. yesterday and set a price target of $30.00. The company’s shares closed yesterday at $14.49.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Van Buren covers the Healthcare sector, focusing on stocks such as Travere Therapeutics, Odyssey Therapeutics, Inc., and Oruka Therapeutics. According to TipRanks, Van Buren has an average return of 39.3% and a 63.60% success rate on recommended stocks.
Biohaven Ltd. has an analyst consensus of Moderate Buy, with a price target consensus of $17.80, representing a 22.84% upside. In a report released yesterday, Canaccord Genuity also reiterated a Buy rating on the stock with a $21.00 price target.